{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:47:22Z","timestamp":1791010042316,"version":"4.1.0"},"reference-count":60,"publisher":"Bioscientifica","issue":"7","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for metabolic diseases, but their reproductive safety remains controversial. We assessed the impact of periconceptional GLP-1RA exposure on birth outcomes to inform their use in reproductive-aged women. PubMed, Embase, Web of Science (through December 2025) were searched for randomized controlled trials (RCTs)\/cohorts reporting offspring or pregnancy outcomes in women exposed to GLP-1RAs within three months before conception or during pregnancy. The primary outcome was major congenital malformations (MCMs), compared between neonates with or without maternal GLP-1RA exposure. Secondary outcomes were spontaneous abortion, stillbirth, preterm birth, large for gestational age (LGA), and small for gestational age (SGA). One prospective and five retrospective studies involving 286,599 women (43,577 exposed and 243,022 unexposed to GLP-1RAs) were included. Meta-analysis showed no significant difference in MCM risk in the GLP-1RA exposure group, compared with the non-exposure group (relative risk (RR): 1.02, 95% CI: 0.96\u20131.08). Risks of preterm birth (RR: 1.09, 95% CI: 0.80\u20131.49), LGA (RR: 2.31, 95% CI: 0.56\u20139.44), SGA (RR: 0.71, 95% CI: 0.39\u20131.27), and stillbirth (RR: 1.16, 95% CI: 0.24\u20135.69) were not significantly elevated. The incidence of spontaneous abortion was comparable between the two groups in one study. Evidence suggests that periconceptional GLP-1RA exposure in women is not associated with an increased risk of MCMs or other adverse birth outcomes. However, given the observational design and limited exposed pregnancies, these findings should not be interpreted as proof of safety. Large prospective cohorts and RCTs are needed to confirm the safety of GLP-1RA usage before pregnancy.<\/jats:p>","DOI":"10.1530\/ec-26-0280","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:38:13Z","timestamp":1784212693000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":1,"title":["Periconceptional use of GLP-1 receptor agonists and the risk of major congenital malformations: a systematic review and meta-analysis"],"prefix":"10.1530","volume":"15","author":[{"given":"Xiangxian","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University Third Hospital 1 , ,","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3601-2032","authenticated-orcid":true,"given":"Beijia","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University Third Hospital 1 , ,","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[{"name":"National Clinical Research Centre for Obstetrical and Gynecological Diseases, State Key Laboratory of Female Fertility Promotion, Ministry of Education Key Laboratory of Assisted Reproduction, Centre for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital 2 , ,","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haining","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital 3 , ,","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-0196","authenticated-orcid":true,"given":"Ye","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, Peking University Third Hospital 3 , ,","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"2026071610364058100_bib1","article-title":"World Obesity Atlas","author":"World Obesity Federation","year":"2025"},{"key":"2026071610364058100_bib2","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1097\/AOG.0000000000004395","article-title":"Obesity in pregnancy: ACOG practice bulletin, number 230","volume":"137","author":"American College of Obstetricians and Gynecologists\u2019 Committee on Practice Bulletins\u2013Obstetrics","year":"2021","journal-title":"Obstet Gynecol"},{"key":"2026071610364058100_bib3","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.3390\/nu17233704","article-title":"Obesity and its role in fetal programming \u2013 a narrative review","volume":"17","author":"Mierzy\u0144ski","year":"2025","journal-title":"Nutrients"},{"key":"2026071610364058100_bib4","doi-asserted-by":"crossref","first-page":"E747","DOI":"10.1503\/cmaj.221343","article-title":"Pregnancy in people living with obesity","volume":"195","author":"Oguntala","year":"2023","journal-title":"Can Med Assoc J"},{"key":"2026071610364058100_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13679-025-00629-9","article-title":"When weight matters: how obesity impacts reproductive health and pregnancy-a systematic review","volume":"14","author":"Barbouni","year":"2025","journal-title":"Curr Obes Rep"},{"key":"2026071610364058100_bib6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2213-8587(25)00127-5","article-title":"Parental preconception BMI and risk of adverse birth outcomes in 8 million parent-child triads: a nationwide population-based cohort study in China","volume":"13","author":"Liu","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026071610364058100_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJMra1801040","article-title":"Obesity in pregnancy","volume":"387","author":"Creanga","year":"2022","journal-title":"N Engl J Med"},{"key":"2026071610364058100_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.868441","article-title":"The impact of maternal obesity on offspring cardiovascular health: a systematic literature review","volume":"13","author":"Kankowski","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026071610364058100_bib9","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1007\/s00125-017-4314-3","article-title":"Improved pregnancy outcomes in women with type 1 and type 2 diabetes but substantial clinic-to-clinic variations: a prospective nationwide study","volume":"60","author":"Murphy","year":"2017","journal-title":"Diabetologia"},{"key":"2026071610364058100_bib10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41574-019-0197-3","article-title":"Improving pregnancy outcomes in women with diabetes mellitus: modern management","volume":"15","author":"Ringholm","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"2026071610364058100_bib11","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/oby.23200","article-title":"Impact of preconception weight loss on fasting glucose and pregnancy outcomes in women with obesity: a randomized trial","volume":"29","author":"Price","year":"2021","journal-title":"Obesity"},{"key":"2026071610364058100_bib12","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/AOG.0000000000000677","article-title":"Weight loss in obese pregnant women and risk for adverse perinatal outcomes","volume":"125","author":"Bogaerts","year":"2015","journal-title":"Obstet Gynecol"},{"key":"2026071610364058100_bib13","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.soard.2011.12.009","article-title":"Downsizing pregnancy complications: a study of paired pregnancy outcomes before and after bariatric surgery","volume":"8","author":"Aricha-Tamir","year":"2012","journal-title":"Surg Obes Relat Dis"},{"key":"2026071610364058100_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-18-0175","article-title":"Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study","volume":"179","author":"Salamun","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2026071610364058100_bib15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12958-025-01447-3","article-title":"Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight\/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial","volume":"23","author":"Chen","year":"2025","journal-title":"Reprod Biol Endocrinol"},{"key":"2026071610364058100_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/humupd\/dmaf021","article-title":"Preconception lifestyle interventions for women-a systematic review and meta-analysis of intervention characteristics and behaviour change techniques","volume":"32","author":"Torkel","year":"2026","journal-title":"Hum Reprod Update"},{"key":"2026071610364058100_bib17","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.2337\/dc25-S015","article-title":"15. Management of diabetes in pregnancy: standards of care in diabetes \u2013 2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"2026071610364058100_bib18","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2337\/dc11-0244","article-title":"Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial","volume":"34","author":"Holmes","year":"2011","journal-title":"Diabetes Care"},{"key":"2026071610364058100_bib19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"2026071610364058100_bib20","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1038\/s41591-025-03978-z","article-title":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat Med"},{"key":"2026071610364058100_bib21","doi-asserted-by":"crossref","first-page":"R200","DOI":"10.1530\/EC-21-0130","article-title":"How glucagon-like peptide 1 receptor agonists work","volume":"10","author":"Andreasen","year":"2021","journal-title":"Endocr Connect"},{"key":"2026071610364058100_bib22","article-title":"OZEMPIC (semaglutide) injection, for subcutaneous use: highlights of prescribing information","author":"Novo Nordisk Inc","year":"2025"},{"key":"2026071610364058100_bib23","article-title":"TRULICITY (dulaglutide) injection, for subcutaneous use: highlights of prescribing information","author":"Eli Lilly and Company","year":"2026"},{"key":"2026071610364058100_bib24","doi-asserted-by":"crossref","first-page":"E268","DOI":"10.1152\/ajpendo.00361.2023","article-title":"Maternal GLP-1 receptor activation inhibits fetal growth","volume":"326","author":"Qiao","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026071610364058100_bib25","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/humupd\/dmz019","article-title":"The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective","volume":"25","author":"Jensterle","year":"2019","journal-title":"Hum Reprod Update"},{"key":"2026071610364058100_bib26","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1210\/clinem\/dgaf288","article-title":"Preexisting diabetes and pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline","volume":"110","author":"Wyckoff","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071610364058100_bib27","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1001\/jama.2024.7112","article-title":"Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020\u20132023","volume":"331","author":"Lee","year":"2024","journal-title":"JAMA"},{"key":"2026071610364058100_bib28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy","volume":"184","author":"Cesta","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026071610364058100_bib29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization Guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"2026071610364058100_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083550","article-title":"Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six teratology information services","volume":"14","author":"Dao","year":"2024","journal-title":"BMJ Open"},{"key":"2026071610364058100_bib31","doi-asserted-by":"crossref","first-page":"116.e1","DOI":"10.1016\/j.ajog.2025.01.019","article-title":"Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes","volume":"233","author":"Imbroane","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"2026071610364058100_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70021","article-title":"Pregnancy outcomes after semaglutide exposure","volume":"136","author":"Kolding","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026071610364058100_bib33","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/dom.70334","article-title":"Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: a nationwide cohort study in Taiwan","volume":"28","author":"Chou","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026071610364058100_bib34","first-page":"984","article-title":"Glucagon-like peptide-1 receptor agonists among pregnancies with pregestational diabetes and its relationship with congenital malformations","volume":"13","author":"Lewin","year":"2025","journal-title":"Am J Perinatol"},{"key":"2026071610364058100_bib35","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S2213-8587(20)30151-0","article-title":"Maternal obesity and risk of cardiovascular diseases in offspring: a population-based cohort and sibling-controlled study","volume":"8","author":"Razaz","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026071610364058100_bib36","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/humrep\/dex235","article-title":"Weight reduction intervention for obese infertile women prior to IVF: a randomized controlled trial","volume":"32","author":"Einarsson","year":"2017","journal-title":"Hum Reprod"},{"key":"2026071610364058100_bib37","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1056\/NEJMoa1505297","article-title":"Randomized trial of a lifestyle program in obese infertile women","volume":"374","author":"Mutsaerts","year":"2016","journal-title":"N Engl J Med"},{"key":"2026071610364058100_bib38","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","article-title":"Transforming obesity: the advancement of multi-receptor drugs","volume":"187","author":"Kusminski","year":"2024","journal-title":"Cell"},{"key":"2026071610364058100_bib39","doi-asserted-by":"crossref","DOI":"10.1530\/EC-24-0529","article-title":"Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review","volume":"14","author":"Monney","year":"2025","journal-title":"Endocr Connect"},{"key":"2026071610364058100_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch","year":"2022","journal-title":"Fertil Steril"},{"key":"2026071610364058100_bib41","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/cen.13454","article-title":"Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome","volume":"87","author":"Liu","year":"2017","journal-title":"Clin Endocrinol"},{"key":"2026071610364058100_bib42","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00404-022-06700-3","article-title":"Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT","volume":"306","author":"Li","year":"2022","journal-title":"Arch Gynecol Obstet"},{"key":"2026071610364058100_bib43","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/dom.70452","article-title":"Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"28","author":"Lu","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"2026071610364058100_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1215356","article-title":"Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence","volume":"14","author":"Muller","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026071610364058100_bib45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003088-199528030-00005","article-title":"Placental transfer of drugs administered to the mother","volume":"28","author":"Pacifici","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"2026071610364058100_bib46","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1191\/0960327103ht402oa","article-title":"Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4)","volume":"22","author":"Hiles","year":"2003","journal-title":"Hum Exp Toxicol"},{"key":"2026071610364058100_bib47","article-title":"Dulaglutide and pregnancy: a comprehensive safety assessment using the ex vivo placenta perfusion and in vitro models","volume":"16","author":"Kuoni","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026071610364058100_bib48","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/dme.12726","article-title":"Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with type 2 diabetes","volume":"32","author":"Greco","year":"2015","journal-title":"Diabet Med"},{"key":"2026071610364058100_bib49","article-title":"A case report of a pregnant woman with type 2 diabetes mellitus using dulaglutide during the first trimester of pregnancy","volume":"15","author":"Alghamdi","year":"2023","journal-title":"Cureus"},{"key":"2026071610364058100_bib50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00592-022-01954-4","article-title":"A case report on use of dulaglutide during the first weeks of pregnancy in woman affected by type 2 diabetes mellitus","volume":"60","author":"Burlina","year":"2023","journal-title":"Acta Diabetol"},{"key":"2026071610364058100_bib51","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2174\/0118715303252109231023115112","article-title":"Case series: exposure to glucagon-like peptide-1 receptor agonist in the first trimester of pregnancy in two siblings","volume":"24","author":"Do\u011fan","year":"2024","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"2026071610364058100_bib52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/B978-0-323-47912-7.00008-1","volume-title":"Yen & Jaffe\u2019s Reproductive Endocrinology","author":"Strauss","year":"2019","edition":"edn 8"},{"key":"2026071610364058100_bib53","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/jamainternmed.2025.0290","article-title":"Risk of major congenital malformations following prenatal exposure to smoking cessation medicines","volume":"185","author":"Tran","year":"2025","journal-title":"JAMA Intern Med"},{"key":"2026071610364058100_bib54","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.5723","article-title":"Preconception thyrotropin levels and risk of adverse pregnancy outcomes in Chinese women aged 20 to 49 years","volume":"4","author":"Yang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026071610364058100_bib55","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1001\/jama.2025.20951","article-title":"Gestational weight gain and pregnancy outcomes after GLP-1 receptor agonist discontinuation","volume":"334","author":"Maya","year":"2025","journal-title":"JAMA"},{"key":"2026071610364058100_bib56","first-page":"950","article-title":"Expert consensus on clinical application of incretin-based weight-loss medications (2025 edition)","volume":"17","author":"Chinese Endocrinologist Association, Chinese Medical Doctor Association, Endocrinology and Metabolism Obesity Diagnosis and Treatment Alliance","year":"2025","journal-title":"Chin J Diabetes Mellitus"},{"key":"2026071610364058100_bib57","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jamacardio.2025.0637","article-title":"Periconceptional glucagon-like peptide-1 receptor agonist use and discontinuation","volume":"10","author":"Khan","year":"2025","journal-title":"JAMA Cardiol"},{"key":"2026071610364058100_bib58","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/jama.2024.22284","article-title":"Discontinuation of glucagon-like peptide-1 receptor agonists","volume":"333","author":"Khan","year":"2025","journal-title":"JAMA"},{"key":"2026071610364058100_bib59","article-title":"Liraglutide treatment in obese infertile PCOS women","author":"Wang","year":"2024"},{"key":"2026071610364058100_bib60","article-title":"Wegovy\u00ae (semaglutide 2.4 mg) database study: a population-based cohort study to investigate safety outcomes of exposure to wegovy during pregnancy","author":"Novo","year":"2022"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-26-0280\/521777\/ec-26-0280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-26-0280\/521777\/ec-26-0280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:38:21Z","timestamp":1784212701000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/15\/7\/e260280\/77775\/Periconceptional-use-of-GLP-1-receptor-agonists"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-26-0280","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"e260280"}}